Schering-Plough withdraws EU application for Cylatron in melanoma
This article was originally published in Scrip
Executive Summary
Schering-Ploughhas withdrawn its EU application to market Cylatron (peginterferon alfa-2b) for the adjuvant treatment of stage III resected melanoma.